EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Cell-free DNA for the detection of kidney allograft rejection

Olivier Aubert iD, Cindy Ursule-Dufait, Romain Brousse, Juliette Gueguen, Maud Racapé, Marc Raynaud, Elisabet Van Loon iD, Angelica Pagliazzi, Edmund Huang iD, Stanley C Jordan iD, Kenneth D Chavin, Gaurav Gupta und 16 weitere

Nature Medicine · 2024-08 · 30 (8) · 2320-2327

DOI: 10.1038/s41591-024-03087-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nature Medicine, online erschienen am 02.06.2024. Verfasst von Olivier Aubert und 27 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM U970, Paris Institute for Transplantation and Organ Regeneration, Paris, France. Hauptthemen laut MEDLINE: Graft Rejection, Kidney Transplantation, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 172-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OrganX Fundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Donor-derived cell-free DNA (dd-cfDNA) is an emerging noninvasive biomarker that has the potential to detect allograft injury. The capacity of dd-cfDNA to detect kidney allograft rejection and its added clinical value beyond standard of care patient monitoring is unclear. We enrolled 2,882 kidney allograft recipients from 14 transplantation centers in Europe and the United States in an observational population-based study. The primary analysis included 1,134 patients. Donor-derived cell-free DNA levels strongly correlated with allograft rejection, including antibody-mediated rejection ( P < 0.0001), T cell-mediated rejection ( P < 0.0001) and mixed rejection ( P < 0.0001). In multivariable analysis, circulating dd-cfDNA was significantly associated with allograft rejection (odds ratio 2.275; 95% confidence interval (CI) 1.902–2.739; P < 0.0001) independently of standard of care patient monitoring parameters. The inclusion of dd-cfDNA to a standard of care prediction model showed improved discrimination (area under the curve 0.777 (95% CI 0.741–0.811) to 0.821 (95% CI 0.784–0.852); P = 0.0011) and calibration. These results were confirmed in the external validation cohorts ( n = 1,748) including a cohort of African American patients ( n = 439). Finally, dd-cfDNA showed high predictive value to detect subclinical rejection in stable patients. Our study provides insights on the potential value of assessing dd-cfDNA, in addition to standard of care monitoring, to improve the detection of allograft rejection. ClinicalTrials.gov registration: NCT05995379 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionKidney TransplantationCell-Free Nucleic AcidsHumansMaleFemaleMiddle AgedAdultAllograftsBiomarkersTissue DonorsTransplantation, HomologousAged

Substanzen

Cell-Free Nucleic AcidsBiomarkers

Autor:innen und Institutionen

  • Université Paris Cité, INSERM U970, Paris Institute for Transplantation and Organ Regeneration, Paris, France.
  • Department of Kidney Transplantation, Necker Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
  • Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
  • Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA, USA.
  • Division of Abdominal Organ Transplant, Department of Surgery, Temple University Hospital, Philadelphia, PA, USA.
  • Division of Nephrology, Virginia Commonwealth University, Richmond, VA, USA.

ORCID-Profile: Olivier Aubert, Elisabet Van Loon, Edmund Huang, Stanley C Jordan, Dhiren Kumar, Jorge Sanchez-Garcia, Julien Hogan, Darshana M Dadhania, Maarten Naesens, Vikas R Dharnidharka, Dany Anglicheau, Alexandre Loupy

Förderung

  • OrganX Fundation

Zitieren

APA

Aubert, O., Ursule-Dufait, C., Brousse, R., Gueguen, J., Racapé, M., Raynaud, M., Van Loon, E., Pagliazzi, A., Huang, E., Jordan, S. C., Chavin, K. D., Gupta, G., Kumar, D., Alhamad, T., Anand, S., Sanchez-Garcia, J., Abdalla, B. A., Hogan, J., Garro, R., …, & Loupy, A. (2024). Cell-free DNA for the detection of kidney allograft rejection. Nature Medicine, 30(8), 2320-2327. https://doi.org/10.1038/s41591-024-03087-3

Vancouver

Aubert O, Ursule-Dufait C, Brousse R, Gueguen J, Racapé M, Raynaud M, et al. Cell-free DNA for the detection of kidney allograft rejection. Nature Medicine. 2024;30(8):2320-2327. doi:10.1038/s41591-024-03087-3

BibTeX
@article{Aubert2024,
  author = {Aubert, Olivier and Ursule-Dufait, Cindy and Brousse, Romain and Gueguen, Juliette and Racapé, Maud and Raynaud, Marc and Van Loon, Elisabet and Pagliazzi, Angelica and Huang, Edmund and Jordan, Stanley C and Chavin, Kenneth D and Gupta, Gaurav and Kumar, Dhiren and Alhamad, Tarek and Anand, Sanjiv and Sanchez-Garcia, Jorge and Abdalla, Basmah A and Hogan, Julien and Garro, Rouba and Dadhania, Darshana M and Jain, Pranjal and Mandelbrot, Didier A and Naesens, Maarten and Dandamudi, Raja and Dharnidharka, Vikas R and Anglicheau, Dany and Lefaucheur, Carmen and Loupy, Alexandre},
  title = {Cell-free DNA for the detection of kidney allograft rejection},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {8},
  pages = {2320--2327},
  doi = {10.1038/s41591-024-03087-3}
}
Kostenlos starten →